Unknown PHASE3 INTERVENTIONAL 2-arm NCT06071975

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Sponsor: Apurano Pharmaceuticals GmbH

Conditions Chronic Pain Chronic Pain Syndrome Diabetes Diabetic Neuropathies Diabetic Polyneuropathy Pain Pain Syndrome Pain, Chronic Peripheral Neuralgia Peripheral Neuropathy Peripheral Neuropathy With Type 2 Diabetis

Interventions Adezunap (AP707) Placebo

Updated 5 times since 2023 Last updated: Jan 30, 2024 Started: Nov 2, 2023 Primary completion: Sep 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06071975, this PHASE3 trial focuses on Chronic Pain and Chronic Pain Syndrome and remains ongoing. Sponsored by Apurano Pharmaceuticals GmbH, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Apurano Pharmaceuticals GmbH

Data source: Apurano Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany